OLIPHANT LAURA 4
4 · AEHR TEST SYSTEMS · Filed Aug 2, 2023
Insider Transaction Report
Form 4
OLIPHANT LAURA
Director
Transactions
- Exercise/Conversion
Common Stock
2023-07-31$1.68/sh+7,500$12,600→ 7,500 total - Sale
Common Stock
2023-08-01$52.50/sh−1,008$52,920→ 12,665 total(indirect: By Trust) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-07-31−7,500→ 0 totalExercise: $1.68From: 2019-08-17Exp: 2026-07-17→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2023-07-31$1.34/sh+2,500$3,350→ 10,000 total - Sale
Common Stock
2023-07-31$51.67/sh−10,000$516,700→ 0 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-07-31−2,500→ 0 totalExercise: $1.34From: 2020-11-20Exp: 2027-10-20→ Common Stock (2,500 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.65 to $51.81, inclusive. The reporting person undertakes to provide to Aehr Test Systems, any security holder of Aehr Test Systems, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.
- [F2]The amount reported includes shares subject to unvested restricted stock units.
- [F3]One twelfth (1/12) of the total number of shares became exercisable on this date and an additional one twelfth (1/12) of the total number of shares became exercisable each month thereafter.
- [F4]One forty-eighth (1/48) of the total number of shares became exercisable on this date and an additional one forty-eighth (1/48) of the total number of shares became exercisable each month thereafter.